{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:49:14Z","timestamp":1781538554056,"version":"3.54.5"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Skin cutaneous melanoma (SKCM) is a significant oncological challenge due to its aggressive nature and poor treatment outcomes. This study explores the comprehensive effects of radiotherapy (RT) in SKCM, focusing on cell signaling pathways, immune infiltration, immune gene correlations, immunotherapy response, and prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using the Cancer Genome Atlas (TCGA) database, differentially expressed genes (DEGs) in SKCM patients undergoing RT were identified. A risk score model based on these DEGs was developed to assess the effects of RT-related genes on drug sensitivity, immune cell infiltration, immunotherapy response, and prognosis through multi-omics analysis. Human melanoma cells UACC62 and UACC257 were irradiated with 8 Gy gamma ray to establish an <jats:italic>in vitro<\/jats:italic> model, verifying the impact of radiotherapy on gene expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The risk score demonstrated significant prognostic value and emerged as an independent prognostic factor. miRNA-mRNA and transcription factor regulatory networks underscored its clinical significance. Four key genes were identified: DUSP1, CXCL13, SLAMF7, and EVI2B. Analysis of single-cell and immunotherapy datasets indicated that these genes enhance immune response and immunotherapy efficacy in melanoma patients. PCR results confirmed that gamma rays increased the expression of these genes in human melanoma cells UACC62 and UACC257.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Using a multi-omics approach, we analyzed and validated the impact of RT on the immune landscape of melanoma patients. Our findings highlight the critical role of RT-related genes in predicting SKCM prognosis and guiding personalized therapy strategies, particularly in the context of immunotherapy. These contribute to understanding the role of radiotherapy combined with immunotherapy in melanoma.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1467098","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T06:24:28Z","timestamp":1733120668000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Research on the influence of radiotherapy-related genes on immune infiltration, immunotherapy response and prognosis in melanoma based on multi-omics"],"prefix":"10.3389","volume":"15","author":[{"given":"Yujing","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Center"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v12.17","article-title":"Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study)","volume":"12","author":"Namikawa","year":"2023","journal-title":"Cancer Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae045","article-title":"Five-year follow-up of POLARIS-01 phase II trial: toripalimab as salvage monotherapy in chinese patients with advanced melanoma","volume":"29","author":"Tang","year":"2024","journal-title":"Oncologist"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v112:6","article-title":"Adjuvant radiotherapy for cutaneous melanoma","volume":"112","author":"Mendenhall","year":"2008","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239324","article-title":"Immunostimulatory effects of radiotherapy for local and systemic control of melanoma: A review","volume":"21","author":"Takahashi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2023.2280766","article-title":"Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability","volume":"62","author":"Backlund","year":"2023","journal-title":"Acta Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174069","article-title":"Efficacy of large use of combined hypofractionated radiotherapy in a cohort of anti-PD-1 monotherapy-treated melanoma patients","volume":"14","author":"Saiag","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.283","article-title":"BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma","volume":"133","author":"Mann","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.20.00108","article-title":"OncoTree: A cancer classification system for precision oncology","volume":"5","author":"Kundra","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1038\/s41467-022-34877-3","article-title":"A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"B16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab260","article-title":"oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data","volume":"22","author":"Maeser","year":"2021","journal-title":"Brief Bioinform"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts344","article-title":"miRcode: a map of putative microRNA target sites in the long non-coding transcriptome","volume":"28","author":"Jeggari","year":"2012","journal-title":"Bioinformatics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2022.08.004","article-title":"TIGER: A web portal of tumor immunotherapy gene expression resource","volume":"21","author":"Chen","year":"2023","journal-title":"Genomics Proteomics Bioinf"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.9940","article-title":"Tumor infiltrating lymphocytes: The regulator of melanoma evolution","volume":"17","author":"Antohe","year":"2019","journal-title":"Oncol Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133212","article-title":"Tumor microenvironment as A \u201cGame changer\u201d in cancer radiotherapy","volume":"20","author":"Jarosz-Biej","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.05.005","article-title":"Radiotherapy-induced metabolic hallmarks in the tumor microenvironment","volume":"8","author":"Mittal","year":"2022","journal-title":"Trends Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1903827","DOI":"10.1080\/21645515.2021.1903827","article-title":"Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review","volume":"18","author":"Tagliaferri","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.2018.179.issue-6","article-title":"Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC","volume":"179","author":"Brancaccio","year":"2018","journal-title":"Br J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-specific risk of recurrence and death from melanoma in Denmark, 2008-2021: A national observational cohort study of 25 720 patients with stage IA to IV melanoma","volume":"159","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v128.20","article-title":"Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma","volume":"128","author":"Johannet","year":"2022","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14724-5","article-title":"Factors affecting recurrence and survival for patients with high-risk stage II melanoma","volume":"31","author":"Dedeilia","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e32433","DOI":"10.1016\/j.heliyon.2024.e32433","article-title":"Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: A systematic review and meta-analysis","volume":"10","author":"Garutti","year":"2024","journal-title":"Heliyon"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0352","article-title":"Biomarker-driven personalization of neoadjuvant immunotherapy in melanoma","volume":"13","author":"Hoeijmakers","year":"2023","journal-title":"Cancer Discovery"},{"key":"B34","doi-asserted-by":"publisher","first-page":"9235638","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions","volume":"2020","author":"Ralli","year":"2020","journal-title":"J Immunol Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0586","article-title":"Hallmarks of resistance to immune-checkpoint inhibitors","volume":"10","author":"Karasarides","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","article-title":"Mechanisms of immune activation and regulation: lessons from melanoma","volume":"22","author":"Kalaora","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.abp9563","article-title":"Engineered skin bacteria induce antitumor T cell responses against melanoma","volume":"380","author":"Chen","year":"2023","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17148","article-title":"Synergistic effects of melatonin on radiosensitization in carbon-ion radiotherapy","volume":"44","author":"Ju","year":"2024","journal-title":"Anticancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"14395","DOI":"10.1038\/s41598-022-18578-x","article-title":"Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance","volume":"12","author":"Singh","year":"2022","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1041-2","article-title":"Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions","volume":"70","author":"Lawan","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/life13020553","article-title":"Revisiting the role of the CXCL13\/CXCR5-associated immune axis in melanoma: potential implications for anti-PD-1-related biomarker research","volume":"13","author":"Hoellwerth","year":"2023","journal-title":"Life (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4049\/jimmunol.2000300","article-title":"SLAMF7 signaling reprograms T cells toward exhaustion in the tumor microenvironment","volume":"206","author":"O\u2019Connell","year":"2021","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1174138","article-title":"SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy","volume":"14","author":"Farhangnia","year":"2023","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6245160","DOI":"10.1155\/2023\/6245160","article-title":"Establishing and validating an aging-related prognostic signature in osteosarcoma","volume":"2023","author":"Ma","year":"2023","journal-title":"Stem Cells Int"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164110","article-title":"EVI2B is a new prognostic biomarker in metastatic melanoma with IFNgamma associated immune infiltration","volume":"13","author":"Yonekura","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1467098\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T06:24:31Z","timestamp":1733120671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1467098\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2024.1467098"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1467098","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"article-number":"1467098"}}